This is an old revision of the document!
Merck
Merck is a multinational pharmaceutical company based in Kenilworth, New Jersey.1)
COVID-19
Ivermectin
Merck is the original patent holder for Ivermectin which has been available for decades and is now off-patent.2) It has proven to be highly effective at preventing and treating COVID-19.3)
Molnupiravir
Merck is producing and marketing an experimental oral mutagenic antiviral pill for COVID-19 called molnupiravir.4) 5) 6)
1)
The Trusted Provider of Medical Information since 1899. Merck Manuals. Retrieved January 18, 2022, from https://archive.ph/nYPYj
2)
Speare, R., & Durrheim, D. (2004). Mass treatment with ivermectin: an underutilized public health strategy. Bulletin of the World
Health Organization, 82(8), 562.
3)
@CovidAnalysis. (2022, January 17). Ivermectin for COVID-19: real-time analysis of all 91 studies. C19Ivermectin. https://archive.ph/rXrxr
4)
Kilgore, T. (2021, December 3). Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pill.
MarketWatch. Retrieved December 5, 2021, from https://archive.ph/gLvZG
5)
Moody, M., Ryan, P., Dannenbaum, P., Kruper, R., & Carvalho, C. (2021, October 1). Merck and Ridgeback’s Investigational Oral
Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients
with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg
6)
Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19. Chemical & Engineering News; American Chemical Society. https://archive.ph/8sJfE